SI2528897T1 - Disubstituirani derivati piridina kot protitumorne uäśinkovine - Google Patents
Disubstituirani derivati piridina kot protitumorne uäśinkovineInfo
- Publication number
- SI2528897T1 SI2528897T1 SI201130359T SI201130359T SI2528897T1 SI 2528897 T1 SI2528897 T1 SI 2528897T1 SI 201130359 T SI201130359 T SI 201130359T SI 201130359 T SI201130359 T SI 201130359T SI 2528897 T1 SI2528897 T1 SI 2528897T1
- Authority
- SI
- Slovenia
- Prior art keywords
- anticancers
- pyridine derivatives
- substituted pyridine
- substituted
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29963110P | 2010-01-29 | 2010-01-29 | |
US35972910P | 2010-06-29 | 2010-06-29 | |
PCT/JP2011/052302 WO2011093524A1 (en) | 2010-01-29 | 2011-01-28 | Di - substituted pyridine derivatives as anticancers |
EP11705048.4A EP2528897B9 (en) | 2010-01-29 | 2011-01-28 | Di-substituted pyridine derivatives as anticancers |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2528897T1 true SI2528897T1 (sl) | 2015-02-27 |
Family
ID=43797869
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201130359T SI2528897T1 (sl) | 2010-01-29 | 2011-01-28 | Disubstituirani derivati piridina kot protitumorne uäśinkovine |
Country Status (27)
Country | Link |
---|---|
US (1) | US8722663B2 (sl) |
EP (1) | EP2528897B9 (sl) |
JP (1) | JP5335932B2 (sl) |
KR (1) | KR101411030B1 (sl) |
CN (1) | CN102791690B (sl) |
AR (1) | AR080057A1 (sl) |
AU (1) | AU2011211306B2 (sl) |
CA (1) | CA2788073A1 (sl) |
CO (1) | CO6561817A2 (sl) |
DK (1) | DK2528897T3 (sl) |
EA (1) | EA026042B1 (sl) |
ES (1) | ES2521016T3 (sl) |
HK (1) | HK1178523A1 (sl) |
HR (1) | HRP20141190T1 (sl) |
IL (1) | IL221146A (sl) |
MX (1) | MX2012008391A (sl) |
MY (1) | MY160875A (sl) |
NZ (1) | NZ601794A (sl) |
PL (1) | PL2528897T3 (sl) |
PT (1) | PT2528897E (sl) |
RS (1) | RS53705B1 (sl) |
SG (1) | SG182663A1 (sl) |
SI (1) | SI2528897T1 (sl) |
SM (1) | SMT201500007B (sl) |
TW (1) | TWI404713B (sl) |
UA (1) | UA107692C2 (sl) |
WO (1) | WO2011093524A1 (sl) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013047223A (ja) * | 2011-07-28 | 2013-03-07 | Otsuka Pharmaceut Co Ltd | 医薬 |
MX2015012062A (es) | 2013-03-14 | 2016-05-05 | Tolero Pharmaceuticals Inc | Inhibidores de jak2 y alk2 y metodos para su uso. |
UY35464A (es) | 2013-03-15 | 2014-10-31 | Araxes Pharma Llc | Inhibidores covalentes de kras g12c. |
US9745319B2 (en) | 2013-03-15 | 2017-08-29 | Araxes Pharma Llc | Irreversible covalent inhibitors of the GTPase K-Ras G12C |
US10800751B2 (en) * | 2013-08-23 | 2020-10-13 | Virginia Commonwealth University | Ester nitrates derivatives of aromatic aldehydes with multiple pharmalogic properties to treat sickle cell disease |
TWI659021B (zh) | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Kras g12c之抑制劑 |
JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
US9862701B2 (en) | 2014-09-25 | 2018-01-09 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
WO2016049568A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Methods and compositions for inhibition of ras |
JP2018513853A (ja) | 2015-04-10 | 2018-05-31 | アラクセス ファーマ エルエルシー | 置換キナゾリン化合物およびその使用方法 |
JP6789239B2 (ja) | 2015-04-15 | 2020-11-25 | アラクセス ファーマ エルエルシー | Krasの縮合三環系インヒビターおよびその使用の方法 |
US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
WO2017058805A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
WO2017058768A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
US10975071B2 (en) | 2015-09-28 | 2021-04-13 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
WO2017058902A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
EP3356359B1 (en) | 2015-09-28 | 2021-10-20 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
EP3356353A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
US10875842B2 (en) | 2015-09-28 | 2020-12-29 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
WO2017070256A2 (en) | 2015-10-19 | 2017-04-27 | Araxes Pharma Llc | Method for screening inhibitors of ras |
EP3377481A1 (en) | 2015-11-16 | 2018-09-26 | Araxes Pharma LLC | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof |
US9988357B2 (en) | 2015-12-09 | 2018-06-05 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
WO2017172979A1 (en) | 2016-03-30 | 2017-10-05 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
EP3519402A1 (en) | 2016-09-29 | 2019-08-07 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
JP2019534260A (ja) | 2016-10-07 | 2019-11-28 | アラクセス ファーマ エルエルシー | Rasの阻害剤としての複素環式化合物およびその使用方法 |
EP3573954A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
JP7327802B2 (ja) | 2017-01-26 | 2023-08-16 | アラクセス ファーマ エルエルシー | 縮合ヘテロ-ヘテロ二環式化合物およびその使用方法 |
WO2018140513A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
WO2018140514A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
EP3573964A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Benzothiophene and benzothiazole compounds and methods of use thereof |
BR112019024674A2 (pt) | 2017-05-25 | 2020-06-16 | Araxes Pharma Llc | Inibidores covalentes da kras |
WO2018218069A1 (en) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant kras, hras or nras |
CN110869357A (zh) | 2017-05-25 | 2020-03-06 | 亚瑞克西斯制药公司 | 化合物及其用于治疗癌症的使用方法 |
WO2019195753A1 (en) | 2018-04-05 | 2019-10-10 | Tolero Pharmaceuticals, Inc. | Axl kinase inhibitors and use of the same |
WO2020023910A1 (en) | 2018-07-26 | 2020-01-30 | Tolero Pharmaceuticals, Inc. | Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same |
CN112812781B (zh) * | 2021-01-21 | 2023-09-29 | 西安瑞联新材料股份有限公司 | 一种基于双哌嗪类苯并噁唑液晶化合物及其制备方法 |
CN116903587B (zh) * | 2023-06-01 | 2024-03-22 | 三峡大学 | 一种角鲨烯环氧酶抑制剂及其用途 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63301880A (ja) * | 1985-09-03 | 1988-12-08 | Otsuka Pharmaceut Co Ltd | 5−フルオロウラシル誘導体 |
AR015733A1 (es) * | 1998-03-25 | 2001-05-16 | Otsuka Pharma Co Ltd | DERIVADO DE PIRIDINA, EL PRODUCTO Y LA COMPOSICIoN FARMACEUTICA QUE CONTIENE DICHO DERIVADO. |
US6262088B1 (en) * | 1998-11-19 | 2001-07-17 | Berlex Laboratories, Inc. | Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants |
JP2001089450A (ja) * | 1999-09-22 | 2001-04-03 | Otsuka Pharmaceut Co Ltd | ピリジン誘導体含有医薬製剤 |
JP2001089412A (ja) * | 1999-09-22 | 2001-04-03 | Otsuka Pharmaceut Co Ltd | ベンゼン誘導体またはその医薬的に許容される塩 |
JP2002226429A (ja) * | 2001-02-06 | 2002-08-14 | Fuji Photo Film Co Ltd | アクリル酸エステル化合物の製造方法 |
GB0224917D0 (en) * | 2002-10-25 | 2002-12-04 | Novartis Ag | Organic compounds |
BRPI0514150A (pt) * | 2004-08-06 | 2007-11-27 | Otsuka Pharma Co Ltd | composto aromático ou um sal do mesmo, método para produzir o mesmo, e, composição farmacêutica para tratar a fibrose |
US8236826B2 (en) | 2005-12-05 | 2012-08-07 | Otsuka Pharmaceutical Co., Ltd. | Diarylether derivatives as antitumor agents |
JP5142513B2 (ja) * | 2005-12-05 | 2013-02-13 | 大塚製薬株式会社 | 医薬 |
UA95978C2 (ru) * | 2006-10-02 | 2011-09-26 | Оцука Фармас'Ютікел Ко., Лтд. | Ингибитор активации stat3/5 |
US20100136509A1 (en) | 2007-07-02 | 2010-06-03 | Alden Mejer | System and method for clinical trial investigator meeting delivery and training including dynamic media enrichment |
TWI440638B (zh) * | 2007-10-30 | 2014-06-11 | Otsuka Pharma Co Ltd | 雜環化合物及其藥學組成物 |
DE202009007345U1 (de) * | 2009-05-22 | 2009-09-10 | Schebo (R) . Biotech Ag | Neue Pharmazeutika und Arzneimittelzubereitungen |
-
2011
- 2011-01-28 AR ARP110100297A patent/AR080057A1/es unknown
- 2011-01-28 CA CA2788073A patent/CA2788073A1/en not_active Abandoned
- 2011-01-28 PT PT117050484T patent/PT2528897E/pt unknown
- 2011-01-28 US US13/318,053 patent/US8722663B2/en not_active Expired - Fee Related
- 2011-01-28 ES ES11705048.4T patent/ES2521016T3/es active Active
- 2011-01-28 RS RS20140688A patent/RS53705B1/en unknown
- 2011-01-28 EA EA201290720A patent/EA026042B1/ru not_active IP Right Cessation
- 2011-01-28 DK DK11705048.4T patent/DK2528897T3/en active
- 2011-01-28 UA UAA201209216A patent/UA107692C2/uk unknown
- 2011-01-28 PL PL11705048T patent/PL2528897T3/pl unknown
- 2011-01-28 JP JP2011545133A patent/JP5335932B2/ja not_active Expired - Fee Related
- 2011-01-28 MY MYPI2012003367A patent/MY160875A/en unknown
- 2011-01-28 EP EP11705048.4A patent/EP2528897B9/en active Active
- 2011-01-28 AU AU2011211306A patent/AU2011211306B2/en not_active Ceased
- 2011-01-28 KR KR1020117025212A patent/KR101411030B1/ko not_active IP Right Cessation
- 2011-01-28 WO PCT/JP2011/052302 patent/WO2011093524A1/en active Application Filing
- 2011-01-28 CN CN201180007162.2A patent/CN102791690B/zh not_active Expired - Fee Related
- 2011-01-28 SI SI201130359T patent/SI2528897T1/sl unknown
- 2011-01-28 NZ NZ601794A patent/NZ601794A/en not_active IP Right Cessation
- 2011-01-28 MX MX2012008391A patent/MX2012008391A/es active IP Right Grant
- 2011-01-28 TW TW100103410A patent/TWI404713B/zh not_active IP Right Cessation
- 2011-01-28 SG SG2012054243A patent/SG182663A1/en unknown
-
2012
- 2012-07-19 CO CO12121461A patent/CO6561817A2/es unknown
- 2012-07-26 IL IL221146A patent/IL221146A/en not_active IP Right Cessation
-
2013
- 2013-05-06 HK HK13105398.2A patent/HK1178523A1/xx not_active IP Right Cessation
-
2014
- 2014-12-09 HR HRP20141190AT patent/HRP20141190T1/hr unknown
-
2015
- 2015-01-09 SM SM201500007T patent/SMT201500007B/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1178523A1 (en) | Di - substituted pyridine derivatives as anticancers | |
HRP20180672T1 (hr) | Novi derivati piridina | |
HK1182594A1 (en) | N3-substituted-n1-sulfonyl-5-fluoropyrimidinone derivatives n3--n1--5- | |
ZA201209117B (en) | Tetrahydro-pyrido-pyrimidine derivatives | |
EP2524917A4 (en) | CONDENSED PYRIDINE DERIVATIVES | |
EP2558094A4 (en) | PYRIDONE DERIVATIVES | |
IL233001A0 (en) | New iso-ergoline histories | |
GB2490849B (en) | Di-aspirin derivatives | |
HUP1000243A2 (en) | 8-hidroxy-quinoline derivatives | |
HK1174625A1 (en) | Pyrrazolopyridine derivatives | |
EP2592076A4 (en) | SUBSTITUTED PYRIDINE COMPOUND | |
HK1206716A1 (en) | Novel pyridine derivatives | |
ZA201209248B (en) | Amido-tropane derivatives | |
IL220983A0 (en) | 2-aldoximino-5-fluoropyrimidine derivatives |